DE2432393C3 - Arzneipräparat zur Behandlung von bösartigen Neubildungen - Google Patents
Arzneipräparat zur Behandlung von bösartigen NeubildungenInfo
- Publication number
- DE2432393C3 DE2432393C3 DE19742432393 DE2432393A DE2432393C3 DE 2432393 C3 DE2432393 C3 DE 2432393C3 DE 19742432393 DE19742432393 DE 19742432393 DE 2432393 A DE2432393 A DE 2432393A DE 2432393 C3 DE2432393 C3 DE 2432393C3
- Authority
- DE
- Germany
- Prior art keywords
- preparation
- animals
- treatment
- tumor
- medicinal preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000002360 preparation method Methods 0.000 title claims description 36
- 206010028980 Neoplasm Diseases 0.000 title description 23
- 201000011510 cancer Diseases 0.000 title description 2
- 239000004480 active ingredient Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 3
- YUXPJMWDDQCARU-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanol;2-(2-methylphenoxy)acetic acid Chemical group OCCN(CCO)CCO.CC1=CC=CC=C1OCC(O)=O YUXPJMWDDQCARU-UHFFFAOYSA-N 0.000 claims description 2
- 239000008063 pharmaceutical solvent Substances 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000005755 formation reaction Methods 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 33
- 241000699670 Mus sp. Species 0.000 description 13
- 230000000694 effects Effects 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 206010039491 Sarcoma Diseases 0.000 description 6
- QJVXBRUGKLCUMY-UHFFFAOYSA-N 2-(2-methylphenoxy)acetic acid Chemical compound CC1=CC=CC=C1OCC(O)=O QJVXBRUGKLCUMY-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 4
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 3
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 208000002908 Brown-Pearce carcinoma Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 201000000274 Carcinosarcoma Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000006268 Sarcoma 180 Diseases 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000002920 convulsive effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 231100000566 intoxication Toxicity 0.000 description 2
- 230000035987 intoxication Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 101150090986 1.5 gene Proteins 0.000 description 1
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000001792 Sarcoma 37 Diseases 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000003327 cancerostatic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 231100000762 chronic effect Toxicity 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000002250 liver carcinoma Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- LCPDWSOZIOUXRV-UHFFFAOYSA-N phenoxyacetic acid Chemical class OC(=O)COC1=CC=CC=C1 LCPDWSOZIOUXRV-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
- C07C59/70—Ethers of hydroxy-acetic acid, e.g. substitutes on the ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU1946758 | 1973-07-05 | ||
| SU1954859A SU515742A1 (ru) | 1973-08-06 | 1973-08-06 | Способ получени трис (2-оксиэтил) аммоний-0-крезоксиацетата |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE2432393A1 DE2432393A1 (de) | 1975-01-30 |
| DE2432393B2 DE2432393B2 (de) | 1978-06-01 |
| DE2432393C3 true DE2432393C3 (de) | 1979-01-25 |
Family
ID=26665493
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19742432393 Expired DE2432393C3 (de) | 1973-07-05 | 1974-07-05 | Arzneipräparat zur Behandlung von bösartigen Neubildungen |
| DE19742432392 Expired DE2432392C3 (de) | 1973-07-05 | 1974-07-05 | Tris-(2-hydroxyäthyl)-ammonium-orthokresoxyazetat, Verfahren zu dessen Herstellung und Arzneimittel auf dessen Basis |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19742432392 Expired DE2432392C3 (de) | 1973-07-05 | 1974-07-05 | Tris-(2-hydroxyäthyl)-ammonium-orthokresoxyazetat, Verfahren zu dessen Herstellung und Arzneimittel auf dessen Basis |
Country Status (6)
| Country | Link |
|---|---|
| CA (1) | CA1036618A (OSRAM) |
| CH (1) | CH599918A5 (OSRAM) |
| DE (2) | DE2432393C3 (OSRAM) |
| FR (2) | FR2235681B1 (OSRAM) |
| GB (2) | GB1452339A (OSRAM) |
| SE (1) | SE399250B (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4283419A (en) * | 1978-11-01 | 1981-08-11 | Voronkov Mikhail G | Preparation for raising the fertility of animals |
| RU2098088C1 (ru) * | 1996-04-10 | 1997-12-10 | Валерий Михайлович Дьяков | Способ получения лекарственного средства (трекрезана) с иммунотропным действием |
| RU2623034C1 (ru) * | 2016-07-28 | 2017-06-21 | Федеральное государственное бюджетное учреждение науки Иркутский институт химии им. А.Е. Фаворского Сибирского отделения Российской академии наук | Противоопухолевое средство |
| RU2700941C1 (ru) * | 2019-07-05 | 2019-09-24 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр реабилитации и курортологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ РК" Минздрава России) | Способ предупреждения развития помутнения роговицы при ее механических травмах |
| RU2703302C1 (ru) * | 2019-07-05 | 2019-10-16 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр реабилитации и курортологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ РК" Минздрава России) | Применение раствора оксиэтиламмония метилфеноксиацетата |
| RU2701178C1 (ru) * | 2019-07-10 | 2019-09-25 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр реабилитации и курортологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ РК" Минздрава России) | Способ ускорения заживления роговицы при ее механических травмах |
-
1974
- 1974-06-27 FR FR7422518A patent/FR2235681B1/fr not_active Expired
- 1974-06-27 FR FR7422519A patent/FR2235682B1/fr not_active Expired
- 1974-07-02 GB GB2920574A patent/GB1452339A/en not_active Expired
- 1974-07-02 GB GB2920674A patent/GB1452340A/en not_active Expired
- 1974-07-04 SE SE7408836A patent/SE399250B/xx not_active IP Right Cessation
- 1974-07-04 CH CH915174A patent/CH599918A5/xx not_active IP Right Cessation
- 1974-07-05 DE DE19742432393 patent/DE2432393C3/de not_active Expired
- 1974-07-05 CA CA204,161A patent/CA1036618A/en not_active Expired
- 1974-07-05 DE DE19742432392 patent/DE2432392C3/de not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| DE2432392A1 (de) | 1975-01-30 |
| FR2235682B1 (OSRAM) | 1977-06-03 |
| CH599918A5 (OSRAM) | 1978-06-15 |
| SE7408836L (OSRAM) | 1975-01-07 |
| DE2432392B2 (de) | 1977-09-01 |
| CA1036618A (en) | 1978-08-15 |
| FR2235681A1 (OSRAM) | 1975-01-31 |
| GB1452340A (en) | 1976-10-13 |
| SE399250B (sv) | 1978-02-06 |
| FR2235681B1 (OSRAM) | 1977-06-03 |
| GB1452339A (en) | 1976-10-13 |
| DE2432393B2 (de) | 1978-06-01 |
| FR2235682A1 (OSRAM) | 1975-01-31 |
| DE2432392C3 (de) | 1978-04-27 |
| DE2432393A1 (de) | 1975-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69909794T2 (de) | Verwendung eines dipeptids für wiederherstellungsprozesse | |
| EP0752246A2 (de) | Kappa-Opiate für entzündliche Darmerkrankungen | |
| DE2432393C3 (de) | Arzneipräparat zur Behandlung von bösartigen Neubildungen | |
| DE3115080A1 (de) | Arzneimittel fuer die orale verabreichung und verfahren zu seiner herstellung | |
| DE69005978T2 (de) | Verwendung von Actinonin zur Herstellung eines Medikamentes zur Inhibierung der Angiogenese. | |
| DE2660486C2 (de) | Verwendung von 2-Hydroxymethyl-3,4,5-trihydroxypiperidin als Arzneimittel | |
| DE2759108A1 (de) | Verwendung von alpha -mercapto-beta- aryl-acrylsaeuren bei der steigerung des zinkgehaltes im serum und im gewebe | |
| EP2136816A2 (de) | Oleylphosphocholin | |
| DE2312134C2 (de) | Anthelmintikum | |
| US9192602B2 (en) | Indication of anthra[2,1,c][1,2,5]thiadiazole-6,11-dione compound in alleviating pain | |
| DE69925900T2 (de) | Prophylaktika und Heilmittel für Störungen der Darmschleimhaut | |
| DE2221281C3 (de) | Pharmazeutische Zubereitungen mit entzündungshemmender und analgetischer Wirkung | |
| CN111265538A (zh) | 杠柳毒苷在制备驱杀鱼类体外寄生虫药物中的应用 | |
| DE2908127A1 (de) | Verwendung von inhibitoren des abbaus von enkephalinen und endorphinen bei der bekaempfung von schmerzzustaenden sowie zur herstellung pharmazeutischer zubereitungen und arzneimittel | |
| RU2523792C1 (ru) | Лекарственное средство для лечения туберкулеза | |
| DE2349186A1 (de) | Arzneimittel zur verbesserung der zellatmung, der herzmuskelleistung und der hirnfunktion und verfahren zu seiner herstellung | |
| DE2748015A1 (de) | Arzneimittel zur heilung von boesartigen neubildungen | |
| Lehman et al. | Cinchophen Toxicosis: Results of Experimental Subacute and Chronic Cinchophen Poisoning | |
| DE2644941C3 (de) | Arzneimittel zur Behandlung bösartiger Erkrankungen des lymphoproliferativen Systems | |
| DE1912130A1 (de) | Cholinoleat und Mittel zur Behandlung von Krankheiten der Leber,der Gallenblase und der Bauchspeicheldruese | |
| TWI672145B (zh) | 預防及／或治療代謝疾病的醫藥組合物及其用途 | |
| US9284281B2 (en) | Indication of naphtho[2,3-F]quinoxaline-7,12-dione compound in alleviating pain | |
| DE19923961A1 (de) | Verwendung von 15-Deoxyspergualin zur Behandlung von hyperreaktiven entzündlichen Erkrankungen und Autoimmunerkrankungen | |
| DE2511588A1 (de) | Neues mittel zur prophylaxe und therapie von dehydratationen in der veterinaermedizin, verfahren zu dessen herstellung und seine neue anwendung | |
| DE658531C (de) | Verfahren zur Herstellung eines peroral wirksamen fluessigen Heilmittels |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C3 | Grant after two publication steps (3rd publication) | ||
| 8328 | Change in the person/name/address of the agent |
Free format text: VON FUENER, A., DIPL.-CHEM. DR.RER.NAT. EBBINGHAUS, D., DIPL.-ING., PAT.-ANW., 8000 MUENCHEN |
|
| 8339 | Ceased/non-payment of the annual fee |